Treatment of Overactive Bladder and Interstitial Cystitis

Assessment and Treatment Outcomes

The American Urological Association recommends assessing treatment success or failure at 2-4 weeks for antimuscarinic therapy and 3 months for beta-3 agonists, with annual follow-up for successful treatment to detect any changes in symptoms 1
Reassessment and consideration of alternative or advanced therapies is advised if treatment fails and the patient is not satisfied, as recommended by the American Urological Association 1

Behavioral modifications, such as altering urine concentration/volume through fluid management, avoiding bladder irritants, using elimination diet to identify trigger foods, applying heat or cold over bladder or perineum for symptom relief, and implementing pelvic floor muscle relaxation techniques, can improve symptoms, as recommended by the American Urological Association 2
Establishing a timed voiding schedule based on the patient's bladder diary, starting with short intervals (1-2 hours) and gradually increasing as control improves, is recommended, as suggested by the American Urological Association 3
Reducing fluid intake by approximately 25% and eliminating or significantly reducing caffeine intake can help manage symptoms, as suggested by the American Urological Association 4
Weight loss of even 8% can reduce incontinence episodes by up to 47% in overweight patients, highlighting the importance of weight management in OAB treatment, as recommended by the American Urological Association 5, 4

Beta-3 adrenoceptor agonists, such as mirabegron, are recommended as the preferred first-line pharmacological treatment for overactive bladder (OAB), followed by antimuscarinic medications if needed, due to their efficacy and lower risk of cognitive side effects, as recommended by the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 6, 4, 7
Antimuscarinic medications, such as Oxybutynin, Tolterodine, Trospium, Solifenacin, and Darifenacin, are recommended for patients who do not respond to beta-3 agonists, as suggested by the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 8
Combination therapy with an antimuscarinic and beta-3 adrenoceptor agonist may be considered for patients refractory to monotherapy, with most evidence supporting the combination of solifenacin (5 mg) with mirabegron (25 or 50 mg), as recommended by the European Association of Urology 7
Tricyclic antidepressants (TCAs) should be reserved for carefully evaluated patients who have failed first and second-line therapies, as suggested by the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 8

Stress management practices, including meditation and imagery techniques, can help improve coping techniques and manage stress-induced symptom exacerbations, as recommended by the American Urological Association 2
Behavioral therapies, including bladder training, pelvic floor muscle training, and fluid management, are as effective as antimuscarinic medications in reducing OAB symptoms and have no risk of adverse effects, as recommended by the American Urological Association 4
Sacral neuromodulation, tibial nerve stimulation, or botulinum toxin may be considered as third-line options for patients with overactive bladder, as recommended by the American Urological Association 6
Intradetrusor onabotulinumtoxinA (100 U), sacral neuromodulation (SNS), and peripheral tibial nerve stimulation (PTNS) may be considered for patients who fail or cannot tolerate first and second-line therapies, as recommended by the International Continence Society and the American Urological Association 6, 8

For patients with renal impairment, the dosage of mirabegron should be adjusted based on the estimated glomerular filtration rate (eGFR), as recommended by the American Urological Association 4
For patients with hepatic impairment, the dosage of mirabegron should be adjusted based on the Child-Pugh score, as recommended by the American Urological Association 4
For elderly patients (>65 years), starting with lower doses of oxybutynin (2.5mg twice daily) or considering mirabegron 25mg daily can help minimize cognitive side effects, as advised by the American Geriatrics Society 7
Antimuscarinic medications should be used with extreme caution in elderly patients, patients with narrow-angle glaucoma, patients with impaired gastric emptying, and patients with a history of urinary retention, due to the increased risk of cognitive effects and other adverse events, as recommended by the American Urological Association 6, 8

For dry mouth, consider switching to extended-release oxybutynin or transdermal formulation, as recommended by the American Urological Association 4
For constipation, increase fluid and fiber intake, and consider stool softeners, as recommended by the American Urological Association 4
For urinary retention, check post-void residual, and consider dose reduction or discontinuation if >200 mL, as recommended by the American Urological Association 4